← Back to Clinical Trials
Recruiting NCT05682118

NCT05682118 Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05682118
Status Recruiting
Phase
Sponsor Yonsei University
Condition Ischemic Heart Disease
Study Type INTERVENTIONAL
Enrollment 226 participants
Start Date 2023-07-31
Primary Completion 2026-11-27

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
roadmapiFR/FFR

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 226 participants in total. It began in 2023-07-31 with a primary completion date of 2026-11-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In patients with 50-90% stenosis of the coronary artery, the coronary roadmap (dynamic roadmap) is performed when the conventional fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are performed. coronary roadmap system) to confirm the effectiveness of the function.

Eligibility Criteria

Inclusion Criteria: 1. Patients aged 19 years or older 2. Patients with stable angina, including asymptomatic ischemic heart disease, who have 50-90% stenosis of the causative vessel by coronary angiography 3. Acute coronary syndrome patients with multivessel disease and 50-90% stenosis of non-caused vessels that did not cause acute coronary syndrome 4. Patients who voluntarily decided to participate in this study and gave written consent to the subject consent form Exclusion Criteria: 1. Patients with acute coronary syndrome and single vessel disease 2. Patients who have undergone previous coronary artery bypass grafting 3. Poor coronary blood flow (TIMI grade ≤ 2) 4. If life expectancy is less than one year 5. Women who are pregnant or wish to become pregnant

Contact & Investigator

Central Contact

Yongcheol Kim, MD, PhD

✉ yongcheol@yuhs.ac

📞 +823151898967

Principal Investigator

Yongcheol Kim, MD, PhD

PRINCIPAL INVESTIGATOR

Severance Hospital

Frequently Asked Questions

Who can join the NCT05682118 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Ischemic Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05682118 currently recruiting?

Yes, NCT05682118 is actively recruiting participants. Contact the research team at yongcheol@yuhs.ac for enrollment information.

Where is the NCT05682118 trial being conducted?

This trial is being conducted at Yongin, South Korea.

Who is sponsoring the NCT05682118 clinical trial?

NCT05682118 is sponsored by Yonsei University. The principal investigator is Yongcheol Kim, MD, PhD at Severance Hospital. The trial plans to enroll 226 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology